Welcome to our dedicated page for Inscorp news (Ticker: IBTN), a resource for investors and traders seeking the latest updates and insights on Inscorp stock.
InsCorp, Inc. (OTCQX: IBTN) is the parent of INSBANK, a Nashville-based commercial bank that reports detailed financial and operational updates through regular press releases. This news page aggregates coverage of InsCorp and INSBANK, including quarterly and annual earnings, balance sheet trends, and developments in the bank’s commercial and healthcare-focused lending activities.
Readers can follow how InsCorp reports changes in net interest income, noninterest income, efficiency ratios, and returns on assets and equity. Company announcements often highlight loan growth across commercial and industrial, commercial real estate, construction and development, residential, multifamily, and home equity lines of credit, as well as deposit growth and shifts in funding mix. Management commentary also addresses capital ratios, liquidity, and asset quality measures such as nonperforming loans, net charge-offs, and allowance for credit losses.
Because INSBANK operates specialized divisions—Medquity, TMA Medical Banking, and Finworth—news items frequently discuss healthcare banking performance, nationwide healthcare loan growth, and nationally available virtual private client deposit services. Updates on personnel, such as senior management appointments, and board decisions on dividends and share repurchase authorizations are also part of the company’s news flow.
Investors and observers who monitor IBTN news can use this page to review InsCorp’s commentary on market conditions in middle Tennessee, the evolution of its loan pipeline, and responses to specific events, including the reported incident of apparent loan fraud at INSBANK. Bookmark this feed to see how the company’s reported metrics and strategic priorities develop over time.
InsCorp (OTCQX: IBTN) reported 2025 and 4Q25 results highlighting asset growth past $1 billion, a quarterly dividend increase to $0.12 per share, and a new board director with healthcare expertise.
2025 EPS fell to $1.52 from $2.55 in 2024, impacted by a $4.95M pretax charge from a single fraudulent loan; deposits rose 19% Y/Y and loans grew 13% Y/Y with a 35% Y/Y pipeline increase.
InsCorp (OTCQX: IBTN) disclosed an apparent $5.0 million loan fraud affecting a single credit relationship, and expects a fourth-quarter 2025 loss after charging off the full balance while pursuing recovery.
The company said the event is isolated, the bank remains well-capitalized with $962.3 million total assets as of Sept. 30, 2025, $118.1 million total risk-based capital (13.30%), and an allowance for credit losses equal to 1.34% of total loans of $808.6 million. Management expects the company to remain profitable for the full year ended Dec. 31, 2025, and plans a third-party audit of lending practices while pursuing legal remedies.
InsCorp (OTCQX: IBTN) reported 3Q25 EPS of $0.79 versus $0.64 a year ago and $0.73 in 2Q25, supporting reported net income growth and operating investment. Revenue rose 18% Y/Y to $7.9M while net interest income grew 25% Y/Y and net interest margin expanded 25 bps Y/Y to 3.20%. Average loans increased 17% Y/Y to $811M and average earning assets were $926M. Deposits grew 16% Y/Y. Efficiency ratio was 64.6%; noninterest expenses increased 24% Y/Y. Board approved a quarterly dividend of $0.11 payable Dec 5, 2025.
InsCorp (OTCQX: IBTN) reported strong Q2 2025 results with EPS of $0.73, up from $0.57 in Q1 2025 and $0.63 in Q2 2024. The company demonstrated improved performance with ROA of 0.91% and efficiency ratio of 60.9%. Revenue grew 24% year-over-year, while net interest income increased 27%. The bank's loan portfolio expanded 17% Y/Y, with strong growth across multiple segments.
Notable highlights include the appointment of Billie Jo Parker as Chief Banking & Development Officer, a 10% increase in quarterly dividend to $0.44 annualized, and the repurchase of 33,000 shares. Asset quality remained strong with zero net charge-offs and nonperforming loans at 0.65%. The bank maintained a solid capital position with a tier-1 leverage ratio of 11.28% and tangible book value per share growth of 6.4% Y/Y to $26.48.
INSBANK reported Q1 2025 earnings with EPS of $0.57, compared to $0.66 in Q4 2024 and $0.61 in Q1 2024. The bank achieved 16% year-over-year loan growth and maintained a healthy loan-to-deposit ratio of 100.4%.
Key financial metrics include:
- ROA: 0.74%
- Net interest margin: 3.02%
- Efficiency ratio: 66.1%
- Tangible book value: $25.84 per share
Notable developments include personnel growth of 33% year-over-year and expansion in multiple lending segments, including C&I (21%), Multifamily (32%), and HELOC (51%). The bank's healthcare division, Medquity, continues to provide solid growth with a 13% year-over-year increase.
The Board approved a quarterly dividend of $0.11 per share, representing a 10% increase from 2024. Asset quality remains strong with zero net charge-offs and nonperforming loans at 0.66% of total loans.
INSBANK reported Q1 2025 earnings with EPS of $0.57, compared to $0.66 in Q4 2024 and $0.61 in Q1 2024. The bank achieved solid growth metrics with 16% year-over-year loan growth and 16% deposit growth.
Key performance indicators include:
- ROA of 0.74% and efficiency ratio of 66.1%
- Net interest margin expanded to 3.02%
- Average earning asset growth of 10% year-over-year
- Loan-to-deposit ratio of 100.4%
The bank's Medquity healthcare business continues to provide diversification with 13% year-over-year growth. Personnel expanded to 69 employees, up from 56 a year ago, supporting growth initiatives. Asset quality remains healthy with zero net charge-offs and nonperforming loans at 0.66% of total loans. The Board approved a quarterly dividend of $0.11 per share, representing a 10% increase from 2024.
INSBANK (OTCQX: IBTN) reported Q4 2024 net income of $1.946 million ($0.66 per share), compared to $1.841 million in Q3 2024 and $2.267 million in Q4 2023. The bank achieved record loan growth with originations reaching $99 million in Q4 2024, up from $48 million in Q3. Year-over-year loan growth improved to 12%, with particularly strong performance in healthcare through their Medquity division.
Revenue improved 5% year-over-year to $7.0 million in Q4 2024, while net interest income increased by 5% to $6.391 million. The bank's efficiency ratio was 60.8%, with ROA at 0.88%. The Board approved a quarterly dividend increase of 10% to $0.11 per share, payable March 7, 2025, to shareholders of record February 14, 2025.
InsCorp (OTCQX: IBTN) reported Q3 2024 net income of $1,841,000 ($0.64 per share), compared to $1,820,000 ($0.63 per share) in Q2 2024 and $2,311,000 ($0.80 per share) in Q3 2023. The company saw loan growth of 4% year-over-year and 10% quarter-over-quarter, with strong performance in commercial and industrial loans. Revenue improved 6% quarter-over-quarter to $6,571,000, though declined 3% year-over-year. The Board approved a quarterly dividend of $0.10 per share, representing a 17.6% annualized increase from 2023.
InsCorp, Inc. reported net income of $1,820,000, or $0.63 per share, in Q2 2024, up from $1,763,000 in Q1 2024. The company achieved a ROAE of 10.1% and operating EPS of $0.65. Loan originations increased to $57 million in Q2, up from $23 million in Q1, with strength in Medquity, CRE, C&D, and C&I loans. The loan pipeline grew to $79 million. Medquity reported 9% Y/Y loan growth. Revenue declined 1.1% Y/Y but improved 2.7% LQA to $6,212,000. The net interest margin was 3.08%. Asset quality remains healthy with no net chargeoffs. InsCorp's Board authorized a share repurchase of 125,000 shares and declared a quarterly dividend of $0.10 per share.
InsCorp (IBTN) reported a net profit of $1,763,000 in Q1 2024, with an EPS of $0.61, down from $2,267,000 and $0.79 respectively in Q4 2023. ROA was 1.06% and ROE 9.5% in Q1 2024. Revenue declined slightly to $6,170,000, while the net interest margin decreased to 2.94% in the same period. The bank declared a quarterly cash dividend of $0.10 per share, representing a 17.6% increase from 2023.